Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Chinese Patent Office
McKesson
Johnson and Johnson
Dow
McKinsey
Farmers Insurance
Novartis
Baxter
Merck

Generated: October 24, 2017

DrugPatentWatch Database Preview

Florbetapir f-18 - Generic Drug Details

« Back to Dashboard

What are the generic sources for florbetapir f-18 and what is the scope of florbetapir f-18 freedom to operate?

Florbetapir f-18
is the generic ingredient in one branded drug marketed by Avid Radiopharms Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Florbetapir f-18 has thirty-seven patent family members in thirty countries and thirteen supplementary protection certificates in thirteen countries.

One supplier is listed for this compound.

Summary for Generic Name: florbetapir f-18

US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list1
Clinical Trials: see list34
Patent Applications: see list7
Drug Prices:see low prices
DailyMed Link:florbetapir f-18 at DailyMed

Pharmacology for Ingredient: florbetapir f-18

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-003Apr 6, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-003Apr 6, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-001Apr 6, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-002Apr 6, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-003Apr 6, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-001Apr 6, 2012DISCNNoNo► Subscribe► Subscribe► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-002Apr 6, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-001Apr 6, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-002Apr 6, 2012RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: florbetapir f-18

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,840,866Styrylpyridine derivatives and their use for binding and imaging amyloid plaques► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: florbetapir f-18

Country Document Number Estimated Expiration
European Patent Office2363392► Subscribe
TaiwanI399366► Subscribe
Singapore173338► Subscribe
Costa Rica10329► Subscribe
Guatemala200800201► Subscribe
South Africa200807955► Subscribe
European Patent Office2363391► Subscribe
Serbia52222► Subscribe
Austria539060► Subscribe
World Intellectual Property Organization (WIPO)2007126733► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FLORBETAPIR F-18

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90030-3Sweden► SubscribePRODUCT NAME: FLORBETAPIR (18F); REG. NO/DATE: EU/1/12/805 20130114
13/028Ireland► SubscribePRODUCT NAME: FLORBETAPIR (18F), OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/805 20130114
00600Netherlands► SubscribePRODUCT NAME: FLORBETAPIR ( SUP 18 /SUP F); REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109/01Switzerland► SubscribePRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: SWISSMEDIC 62897 09.01.2014
232Luxembourg► SubscribePRODUCT NAME: FLORBETAPIR (18 F)
/2013Austria► SubscribePRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114
9 5017-2013Slovakia► SubscribePRODUCT NAME: FLORBETAPIR ( 18 F); REGISTRATION NO/DATE: EU/1/12/805 20130114
1Finland► Subscribe
2013000051Germany► SubscribePRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114
2013016Lithuania► SubscribePRODUCT NAME: FLORBETAPIRUM; REGISTRATION NO/DATE: EU/1/12/805 20130114
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Queensland Health
Healthtrust
Boehringer Ingelheim
McKesson
Cantor Fitzgerald
Colorcon
Medtronic
Farmers Insurance
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot